Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Mar 02, 2022 11:14am
230 Views
Post# 34474987

sh*ts and giggles ...

sh*ts and giggles ...I see ENDO has reported its latest quarter.  They beat expectations but the future looks grim.

Dropped from $3.11 to $2.36 at the time of writing.  Man ... they were on their way to $90 when they bought Paladin and started collecting a boat-load of debt to make their acquisitions.

Paladin is stuck at $24M in quarterly revenue - with absolutely no growth over time.  ENDO is paying no attention to the international portion of their business which really tells they have no love for the remaining assets.  Good thing Mark made his exit.

Also looking at ENDO's Q1 2022 guidance ... we see a patent cliff issue is likely to rock their sales in the coming quarter ... hence the drop in stock price in recent days.

Company says ...

"Due to uncertainties in certain key assumptions including the timing and impact of VASOSTRICT® generic competition and the rate and extent to which the market for specialty product office-based procedures recovers from the current COVID-19 driven challenges, the Company is only providing financial guidance for the first quarter ending March 31, 2022 at this time."

As we know from business 101 - if you're going to have an awful quarter then you might as well make it a real awful quarter.  Take that opportunity to do some redecorating and really make some go-forward changes.  Not saying they will.  Just saying that all the planets are aligning for ENDO to clean house ... yet again !!!

Will they look to sell the international business and get something for it ... or ... will they let it die a slow death?  That's the interesting situation they are faced with.

How much does the CEO care?  Does he see the ship sinking (along with the opioid issue) or does he have a recovery plan?  No idea - but - man it's interesting !!!

<< Previous
Bullboard Posts
Next >>